| 000 | 01239 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250517114729.0 | ||
| 264 | 0 | _c20170606 | |
| 008 | 201706s 0 0 eng d | ||
| 022 | _a0890-9091 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPosadas, Edwin M | |
| 245 | 0 | 0 |
_aThird-Line Treatment Options for Kidney Cancer. _h[electronic resource] |
| 260 |
_bOncology (Williston Park, N.Y.) _c09 2016 |
||
| 300 |
_a813-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xgenetics |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 | _aDrug Substitution |
| 650 | 0 | 4 | _aGenetic Predisposition to Disease |
| 650 | 0 | 4 |
_aGenetic Testing _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 | _aPrecision Medicine |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Failure |
| 700 | 1 | _aLimvorasak, Suwicha | |
| 700 | 1 | _aFiglin, Robert A | |
| 773 | 0 |
_tOncology (Williston Park, N.Y.) _gvol. 30 _gno. 9 _gp. 813-5 |
|
| 999 |
_c26423200 _d26423200 |
||